Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Foreword
    Book Section

    Hudis, C.
    In Baum, M. (Eds.) The Scepticaemic Surgeon: How Not to Win Friends and Influence People (2014)

    Fulltext@MSK | Save
  • Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity
    Meeting Abstract

    Yao, Z.; Torres, N. M.; Wei, M.; Hanrahan, A.; Abdel-Wahab, O.; Solit, D.; Luo, L.; Poulikakos, P.; Rosen, N.
    Molecular Cancer Research (2014)

    Fulltext@MSK | Save
  • Piloting IBM Watson Oncology within Memorial Sloan Kettering's regional network
    Meeting Abstract

    Zauderer, M. G.; Gucalp, A.; Epstein, A. S.; Seidman, A. D.; Caroline, A.; Granovsky, S.; Fu, J.; Keesing, J.; Lewis, S.; Co, H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)
    Meeting Abstract

    Traina, T. A.; Kaufman, P. A.; Cadoo, K. A.; Hudis, C. A.; Chang, C.; Berrak, E.; Song, J.; Cox, D.; Seidman, A. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer
    Meeting Abstract

    Traina, T. A.; O'Shaughnessy, J.; Kelly, C. M.; Schwartzberg, L. S.; Gucalp, A.; Peterson, A. C.; Tudor, I. C.; Blaney, M. E.; Steinberg, J. L.; Trudeau, M. E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer
    Meeting Abstract

    Schwartzberg, L. S.; Yardley, D. A.; Elias, A. D.; Patel, M. R.; Gucalp, A.; Burris, H. A.; Peterson, A. C.; Hannah, A. L.; Blaney, M. E.; Gibbons, J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilinournab (ipi)
    Meeting Abstract

    Page, D. B.; Diab, A.; Yuan, J. D.; Dong, Z. W.; Emerson, R.; Robins, H.; Redmond, D.; Zhao, C. J.; Mu, Z. Y.; Wong, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save